Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

GENE - CHEMICAL INTERACTIONS REPORT

CRRD ID: 731380
Species: Homo sapiens
CRRD Object: Gene
Symbol: AIFM1
Name: apoptosis inducing factor mitochondria associated 1
Acc ID: CHEBI:27899
Term: cisplatin
Definition: A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID: MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
QualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
decreases expressionEXP 6480464CTDCisplatin results in decreased expression of AIFM1 protein

PMID:25450742
affects localizationISORGD:7313816480464CTDCisplatin affects the localization of AIFM1 protein

PMID:15983031, PMID:21526214, PMID:26193055
increases expressionISORGD:7313816480464CTDCisplatin results in increased expression of AIFM1 protein

PMID:15983031
multiple interactionsISORGD:7313816480464CTDbenzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Cisplatin affects the localization of AIFM1 protein], erdosteine inhibits the reaction [Cisplatin affects the localization of AIFM1 protein], pifithrin inhibits the reaction [Cisplatin affects the localization of AIFM1 protein], rosemarinic acid inhibits the reaction [Cisplatin affects the localization of AIFM1 protein]

PMID:15983031, PMID:21526214, PMID:26193055
Go Back to source page   Continue to Ontology report

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.